AI Article Synopsis

  • Multiple hereditary exostoses (MHE), also known as multiple osteochondromas, is a genetic disorder leading to multiple bone tumors due to mutations in the EXT1 or EXT2 gene, affecting cartilage growth.
  • Research shows that enhanced bone morphogenetic protein (BMP) signaling, caused by reduced heparan sulfate expression, contributes to the formation of these tumors in MHE.
  • Palovarotene (PVO), a drug candidate previously tested for another bone disorder, significantly reduced osteochondroma formation in mouse models of MHE, suggesting its potential as a therapy for this condition.

Article Abstract

Multiple hereditary exostoses (MHE), also known as multiple osteochondromas (MO), is an autosomal dominant disorder characterized by the development of multiple cartilage-capped bone tumors (osteochondromas). The large majority of patients with MHE carry loss-of-function mutations in the EXT1 or EXT2 gene, which encodes a glycosyltransferase essential for heparan sulfate (HS) biosynthesis. Increasing evidence suggests that enhanced bone morphogenetic protein (BMP) signaling resulting from loss of HS expression plays a role in osteochondroma formation in MHE. Palovarotene (PVO) is a retinoic acid receptor γ selective agonist, which is being investigated as a potential drug for fibrodysplasia ossificans progressiva (FOP), another genetic bone disorder with features that overlap with those of MHE. Here we show that PVO inhibits osteochondroma formation in the Fsp1 ;Ext1 model of MHE. Four-week daily treatment with PVO starting at postnatal day (P) 14 reduced the number of osteochondromas that develop in these mice by up to 91% in a dose-dependent manner. An inhibition of long bone growth observed in animals treated from P14 was almost entirely abrogated by delaying the initiation of treatment to P21. We also found that PVO attenuates BMP signaling in Fsp1 ;Ext1 mice and that aberrant chondrogenic fate determination of Ext1-deficient perichondrial progenitor cells in these mice is restored by PVO. Together, the present data support further preclinical and clinical investigations of PVO as a potential therapeutic agent for MHE. © 2017 American Society for Bone and Mineral Research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895492PMC
http://dx.doi.org/10.1002/jbmr.3341DOI Listing

Publication Analysis

Top Keywords

osteochondroma formation
12
inhibits osteochondroma
8
multiple hereditary
8
hereditary exostoses
8
bmp signaling
8
fsp1 ext1
8
mhe
6
pvo
6
bone
5
palovarotene inhibits
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!